YOLFTbeta
Oscotec Inc

Oscotec Inc

039200 · KQ · Healthcare / Pharmaceuticals

35,800.00KRW+100.00 (+0.28%)

Price History

Full chart

Market Stats

Previous Close35,700.00
Open36,200.00
Day Range35,750.00 – 38,300.00
52-Week Range27,300.00 – 66,000.00
Volume152.33K
Market Cap1.42T
P/E (TTM)0.00
Forward P/E0.00
Dividend Yield0.00%
Beta0.77
50-Day Avg35,247.00
200-Day Avg43,617.50

About

Oscotec Inc. operates as a clinical stage drug discovery and development company. It develops SYK inhibitor that is in Phase IIa clinical trial to treat rheumatoid arthritis and immune thrombocytopenia; FLT3 inhibitor, which is in Phase I clinical trial for the treatment of acute myeloid leukemia; and EGFR double mutation inhibitor to treat non-small cell lung cancer, as well as Anti-Tau antibody, which is in preclinical Phase for the treatment of Alzheimer's disease. The company also offers dental health products, such as bone graft comprising InduCera, BioCera-F, and SynCeraII; and membrane consisting of LysoGide and CollaGuide. In addition, it provides functional ingredients comprises OPB for osteoporosis; AIF for arthritis; SGA that enhance bone growth; and PRF-K for perio diseases. The company was formerly known as Oscotec Co., Ltd and changed its name to Oscotec Inc. in June 1999. Oscotec Inc. was founded in 1988 and is based in Seongnam, South Korea.

Company Details

  • SectorHealthcare
  • IndustryPharmaceuticals
  • CEOSung-Hee Son
  • Employees50
  • HeadquartersA Building, Korea Bio Park, Seongnam-si, South Korea, 13488, Korea
  • Websitehttps://www.oscotec.com

Leadership

  • Sung-Hee SonExec. Officer
  • Se-Nyun KimExec. Officer
  • Hirose DakashiExec. Officer
  • Su-Sung LeeExec. Officer
  • So-Jin AhnExec. Officer
  • Ju-Won KimExec. Officer
  • Jae-Sang LeeExec. Officer
  • Sung-Ho ParkExec. Officer · b. 1968
  • Seung-Chul LeeExec. Officer · b. 1963
  • Mr. Jeung-Keun KimChief Exec. Officer · b. 1960

Financials

Income Statement

Currency: KRW2011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue25.97B24.76B21.86B17.11B18.34B3.55B3.91B18.70B4.37B43.47B3.90B5.06B4.95B34.01B99.84B
Growth (%)--4.66%-11.70%-21.72%+7.16%-80.62%+9.98%+378.51%-76.64%+895.09%-91.02%+29.71%-2.20%+586.89%+193.58%
Cost of Revenue16.27B14.16B12.48B9.50B9.85B1.50B1.69B2.44B2.09B1.89B1.95B2.02B2.03B2.23B1.95B
Gross Profit---7.50B8.48B2.06B2.22B16.27B2.27B41.58B1.95B3.04B2.92B31.78B97.89B
Gross Margin---43.86%46.27%57.92%56.70%86.97%52.05%95.64%49.99%60.02%58.99%93.45%98.05%
Operating Expense---8.26B7.65B6.17B5.88B10.09B22.18B40.22B31.06B32.33B35.58B35.19B45.81B
Operating Income610.17M---756.27M829.14M-4.11B-3.66B6.18B-19.90B1.36B-29.11B-29.30B-32.66B-3.41B52.08B
Operating Margin2.35%---4.42%4.52%-115.59%-93.63%33.03%-455.58%3.13%-745.94%-578.68%-659.64%-10.04%52.17%
EBITDA------------25.90B-30.02B1.91B56.70B
EBITDA Margin------------511.63%-606.35%5.61%56.80%
Net Income----2.02B395.03M-3.65B-3.89B3.47B-22.44B-4.36B-26.26B-24.43B-24.28B876.53M52.34B
Net Income Margin----11.82%2.15%-102.58%-99.61%18.56%-513.57%-10.02%-672.93%-482.57%-490.40%2.58%52.43%
R&D4.00B-3.82B2.14B2.00B6.55B4.82B6.97B15.41B32.79B22.71B23.34B24.91B21.43B27.64B
R&D as % of Total Revenue15.41%-17.48%12.51%10.90%184.21%123.35%37.27%352.74%75.42%581.87%461.10%503.08%63.01%27.68%
Interest Expense000000001.08B709.24M107.65M316.40M406.64M1.09B2.27B
Interest Expense % of Total Revenue0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%24.72%1.63%2.76%6.25%8.21%3.19%2.27%

Balance Sheet

Currency: KRW2011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets47.98B43.05B37.65B36.27B49.50B40.81B40.54B70.26B72.39B76.39B48.97B143.74B132.58B170.78B229.85B
Total Liabilities22.25B18.58B15.48B14.49B22.58B14.49B19.30B23.97B21.11B23.34B20.14B21.23B37.86B38.42B43.01B
Total Equity25.31B24.18B21.49B21.11B26.21B26.33B21.24B46.29B51.29B53.05B28.83B122.51B98.92B127.76B181.31B
Cash713.06M1.69B1.77B878.58M2.08B3.17B19.71B26.36B49.23B5.79B10.58B53.00K7.95B13.11B15.19B
Total Debt-----5.32B5.09B3.75B2.42B1.31B-----
Net Debt-----------4.33B-511.41M293.20M

Cash Flow

Currency: KRW2011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow375.90M3.34B--1.96B646.84M-8.21B-3.69B-5.08B27.47M-17.88B-8.76B-26.42B-22.05B-26.03B8.30B
Investing Cash Flow--2.55B382.06M-10.43B10.73B2.84B-7.92B1.77B-24.39B6.78B-99.64B13.38B-327.66M-
Financing Cash Flow524.25M6.00B-1.38B10.11B-1.33B17.86B19.25B20.81B-1.01B6.26B120.34B11.12B30.35B-
Capital Expenditure1.92B283.88M63.51M157.91M4.16B7.08B61.52M1.72B4.19B5.22B7.52B1.25B581.22M691.95M779.65M
Free Cash Flow----------23.10B-19.11B-27.67B-22.63B-26.73B7.52B
FCF to OCF---------129.21%218.06%104.73%102.64%102.66%90.61%

Earnings

Report DateMar 31, 2009Jun 30, 2009Sep 30, 2009Dec 31, 2009Mar 31, 2010Jun 30, 2010Sep 30, 2010Dec 31, 2010Mar 31, 2011Jun 30, 2011Sep 30, 2011Dec 31, 2011Mar 31, 2012Jun 30, 2012Sep 30, 2012Dec 31, 2012Mar 31, 2013Jun 30, 2013Sep 30, 2013Dec 31, 2013Mar 31, 2014Aug 27, 2014Nov 27, 2014Mar 31, 2015May 15, 2015Aug 13, 2015Oct 30, 2015Feb 1, 2016May 13, 2016Aug 12, 2016Nov 14, 2016Feb 3, 2017May 12, 2017Aug 11, 2017Nov 10, 2017Mar 14, 2018May 15, 2018Aug 14, 2018Nov 14, 2018Jan 23, 2019May 14, 2019Aug 14, 2019Nov 14, 2019Jan 29, 2020May 14, 2020Aug 14, 2020Nov 13, 2020Feb 3, 2021May 14, 2021Aug 13, 2021Nov 15, 2021Mar 7, 2022May 13, 2022Aug 16, 2022Nov 14, 2022Mar 17, 2023May 12, 2023Aug 14, 2023Nov 14, 2023Mar 18, 2024May 14, 2024Aug 14, 2024Nov 12, 2024Feb 26, 2025May 14, 2025Aug 12, 2025Nov 11, 2025Feb 25, 2026May 13, 2026Aug 19, 2026
EPS Estimate---------------------------------------------228.19273.50-253.08-262.27-339.29-256.92-326.25-251.48-----242.78-242.78-242.78-----------
EPS Actual-73.84-27.86-50.25-329.28-47.2120.6432.7617.35-41.6613.88-4.78-108.77-26.8328.25-24.60-602.1237.50-0.17-30.68-181.06-2.30-11.97-7.11-64.32-23.74-14.4754.57-2.42-12.63-131.22-33.2539.64-12.04-42.36-16.89-67.69-16.00-48.00-154.73407.00-167.00-219.26-126.93-361.03-237.00192.00-237.00103.30-321.00-166.00-208.00-288.00-244.02-175.71-205.00-124.28-169.94-169.94-169.94-279.60-142.50-149.44441.99-101.66-155.33-48.28-12.791584.50-71.23958.14
Surprise---------------------------------------------3.86%-29.80%6.35%139.39%5.39%35.39%36.25%-14.52%----30.00%30.00%30.00%-----------
Timing---------------------After-hoursAfter-hoursPre-marketAfter-hoursAfter-hoursPre-marketAfter-hoursPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketAfter-hoursPre-marketPre-marketPre-marketPre-marketPre-marketAfter-hoursPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-market-Pre-marketPre-marketPre-marketPre-marketAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursPre-marketPre-marketPre-marketPre-marketPre-marketPre-market-

Key Statistics & Ratios

Market Cap1.42T
Enterprise Value1.18T
Trailing P/E0.00
Forward P/E0.00
Price / Sales9.51
Price / Book6.34
Revenue (TTM)4.85B
Gross Profit (TTM)1.77B
EBITDA-25.65B
Profit Margin0.00%
Operating Margin-564.93%
Return on Equity35.87%
Return on Assets-28.64%
Shares Outstanding28.10M
Shares Float23.76M
Beta0.77
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Dividends

20081×
10.72Dec 29, 2008
20071×
21.43Dec 27, 2007

Stock Splits

  • Sep 27, 2022832:795
  • Sep 19, 20121234:1137
  • Dec 29, 20092:1
  • Nov 17, 2009648:631